Effect of heterozygous β-thalassaemia trait on coronary atherosclerosis via coronary artery disease risk factors: A preliminary study

Cardiovascular Journal of South Africa

Volumn 18, Issue 3, 2007, Pages 165-168

  Hashemi, M ^a   Shirzadi, E ^b   Talaei, Z ^b   Moghadas, L ^b   Shaygannia, I ^b   Yavari, M ^b   Amiri, N ^b   Taheri, H ^b   Montazeri, H ^b   Shamsolkottabi, H ^c  

^a Noor Hospital   (Iran)

^b UNIVERSITY OF ISFAHAN   (Iran)

^c Sina Hospital   (Iran)

Author keywords

[No Author keywords available]

Indexed keywords

CHOLESTEROL; FERRITIN; HEMOGLOBIN A2; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROTIC PLAQUE; BETA THALASSEMIA; BLOOD CELL COUNT; BLOOD CHEMISTRY; CASE CONTROL STUDY; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; CORONARY RISK; FEMALE; FERRITIN BLOOD LEVEL; GENETIC TRAIT; HEMATOCRIT; HETEROZYGOSITY; HUMAN; IRON DEFICIENCY ANEMIA; LIPID BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; PREVALENCE; RISK ASSESSMENT; TRIACYLGLYCEROL BLOOD LEVEL; CARDIOVASCULAR RISK; CHI SQUARE TEST; CHOLESTEROL BILE LEVEL; INDEPENDENT VARIABLE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; STUDENT T TEST; TWO TAILED TEST;

ADULT; AGED; AGED, 80 AND OVER; BETA-THALASSEMIA; CASE-CONTROL STUDIES; CHI-SQUARE DISTRIBUTION; CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; FEMALE; FERRITINS; HUMANS; LIPOPROTEINS; MALE; MIDDLE AGED; PREVALENCE; RISK FACTORS; TRIGLYCERIDES;

EID: 34548445593     PISSN: 10159657     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Borgnapignatti C, Galanello R. Thalassemias and related disorders: Quantitative disorders of hemoglobin synthesis. In: Greer PJ , Foerster J, Lukens NJ, Rodgers GM, Paraskeves F, Glader B. Wintrobe's Clinical Hematology. 11th edn. Philadelphia: Lippinacott Williams & Wilkins, 2004: 1319.
2. Karimi M, Alavian A, Ghavanini, Kadivar MR. Rigiond mapping of the gene frequerey of β-thalassemia. Irn J Med Sci 2000; 25(384): 734-737.
3. Baserga A, Barrai I, Bonomo L, Carcassi U, Coppo M, Castaldi G, et al. Clinical aspects of beta-thalassaemia minor. Panminer Med 1982; 24(4): 275-277.
4. Crowley JP, Sheth S, Capone RJ, Schilling RF. A paucity of thalassemia trait in Italian men with myocardial infarction. Acta Haematol 1987; 78: 249-251.
5. Wang CH, Schilling RF. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. Am J Hematol 1995; 49(1): 73-75.
6. Gallerian M, Scapldi C, Capone RJ, et al. Thalassemia trait and myocardial infarction: low infarction incidence in male subjects confirmed. J Int Med 1991; 230: 109-111.
7. Namazi MR. Minor thalassemia as a protective factor against cerebrovascular accidents. Med Hypoth 2002; 59(3): 361-362.
8. Rifkind BM, Gale M. Hypolipidemia in anemia. Implications for the epidemiology of ischemic heart disease. Lancet 1967; 2(7517): 640-642.
9. Maioli M, Pettinato S, Cherchi GM, Giraudi D, Pacifico A, Pupita G, et al. Plasma lipids in β-thalassemia minor. Atherosclerosis 1989; 75(2-3): 245-248.
10. Burch GE, de Pasquale NP. Hematocrit, blood viscosity and myocardial infraction. Am J Med 1962; 32: 161-163.
11. Sarnak MJ, Tighiouart H, Manjunath G, Macleod B, Griffith J, Salem D, et al. Anemia as a risk factor for cardiovascular disease in the Atherosclerosis Risk In Communities (ARIC) study. J Am Coll Cardiol 2002; 40(1): 27-33.
12. Brown DW, Giles WH, Croft JB. Hematocrit and the risk of coronary heart disease mortality. Am Heart J 2001; 142(4): 657-663.
13. Piperno A, Mariani R, Arosio C, Vergani A , Rosio S, Fargion S, et al. Haemochromatosis in patients with β-thalassemia. Br J Haematol 2000; 111: 908-914.
14. Parfrey PS, Barnett M, Sachs JA, Pollock DJ, Turnbull AL. Iron overload in beta-thalassaemia minor. A family study. Scand J Haematol 1981; 27(4): 294-302.
15. Queipo de Llano MP, Yebra M, Moreno M, Lacoma F, Gea JC, Berrocal E. Thalassemia minor with iron overload: genetic and clinical study of a family. Med Clin (Barc) 1991; 97(17): 660-662.
16. Christopoulou V, Varsou A, Travlou A, Drivas G. Erythrocyte ferritin in patients with chronic renal failure and heterozygous beta-thalassemia. Nephron 2002; 91(3): 463-467.
17. Da Fonseca SF, Kimura EY, Kerbauy J. Assessment of iron status in individuals with heterozygotic beta-thalassemia. Rev Assoc Med Bras 1995; 41(3): 203-206.
18. Parfrey PS, Squier M. Thalassaemia minor, iron overload and hepatoma. Br Med J 1978; 1(6110): 416.
19. De Valk B, Marx JJ. Iron, atherosclerosis and ischemic heart disease. Arch Intern Med 1999;159(14): 1542-1548.
20. Duffy SJ, Biegelsen ES, Holbrook M, Russell JD, Gokce N, Keaney JF Jr, et al. Iron chelation improves endothelial function in patients with coronary artery disease. Circulation 2001; 103(23): 2799-2804.
21. Horwitz LD, Rosenthal EA. Iron-mediated cardiovascular injury. Vasc Med 1999; 4(2): 93-99.
22. Chau LY. Iron and atherosclerosis. Proc Natl Sci Counc Repub China B 2000; 24(4): 151-155.
23. Iribarren C, Sempos CT, Eckfeldt JH, Folsom AR. Lack of association between ferritin level and measures of LDL oxidation: the ARIC study. Atherosclerosis Risk in Communities. Atherosclerosis 1998; 139(1): 189-195.
24. Timan IS, Funahara Y, Setiabudy R, Latu J, Silman E. PF3 activity in normal subjects and beta-thalassemia trait. SE Asian J Trop Med Publ Hlth 1993; 24(Suppl 1): 216-218.
25. El-Hazmi MA, al-Swailem A, al-Fawaz I, Warsey AS, al-Swailem A. Diabetes mellitus in children suffering from beta-thalassaemia. J Trop Pediatr 1994; 40(5): 261-266.
26. Capaldo B, Tutino L, Patti L, Vaccaro O, Rivellese A, Riccardi G. Lipoprotein composition in individuals with impaired glucose tolerance. Diabet Care 1983; 6(6): 575-578.
27. Smith CS, Goldberg AC. Ischemic heart disease. In: Ahya SN, Flood K, Paranjothi S. The Washington Manual of Medical Therapeutics. 30th edn. Philadelphia: Lippincott Williams & Wilkins, 2001: 96.
28. Johnson CS, Tegos C, Beutler E. Thalassemia minor: routine erythrocyte measurements and differentiation from iron deficiency. Am J Clin Path 1983; 80(1): 31-36.
29. Chalevelakis G, Tsiroyannis K, Hatziioannou J, Arapakis G. Screening for talassaemia and iron deficiency: evaluation of some discrimination functions. Scand J Clin Lab Invest 1984; 44(1): 1-6.
30. England JM, Fraser P. Discrimination between iron-deficiency and heterozygous-thalassaemia syndromes in differential diagnosis of microcytosis. Lancet 1979; 1(8108): 145-148.
31. Huisman TH, Schroeder WA, Brodie AN, Mayson SM, Jakway J. Microchromatography of hemoglobins. II. A simplified procedure for the determination of hemoglobin A2. J Lab Clin Med 1975; 86(4): 700-702.
32. Deiana L, Garuti R, Pes GM, Carru C, Errigo A, Rolleri M, et al. Influence of beta(0)-thalassemia on the phenotypic expression of heterozygous familial hypercholesterolemia: a study of patients with familial hypercholesterolemia from Sardinia. Arterioscler Thromb Vasc Biol 2000; 20(1): 236-243.
33. Maioli M, Pettinato S, Cherchi GM, Giraudi D, Pacifico A, Pupita G, et al. Plasma lipids in beta-thalassemia minor. Atherosclerosis 1989; 75(2-3): 245-248.
34. Aessopos A, Samarkos M, Voskaridou E, Papaioannou D, et al. Arterial calcifications in beta-thalassemia. Angiology 1998; 49(2): 137-140.
35. Maioli M, Pettinato S, Cherchi GM, Giraudi D, Pacifico A, Pupita G, et al. Plasma lipids in beta-thalassemia minor. Atherosclerosis 1989; 75(2-3): 245-248.
36. Shahriari M, Zibaee-Nejad MJ, Bokaee HR. Is minor thalassemia a protective factor against myocardial infarction. Iran J Med Sci 1998; 23(3, 4): 134.
37. Wang CH, Schilling RF. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. Am J Hematol 1995; 49(1): 73-75.
38. Tassiopoulos T, Stamatelos G, Zakopoulos N, Fessas P, Eliopoulos GD. Low incidence of acute myocardial infarction in beta-thalassaemia trait carriers. Haematologia (Budap) 1995; 26(4): 199-203.
39. Eshraghi R. Thalassemia can decrease the risk of myocardial infarction [dissertation]. Thalassemia prevention and research center: Isfahan University; 1997.
40. Wang CH, Schilling RF. Myocardial infarction and thalassemia trait: an example of heterozygote advantage. Am J Hematol 1995; 49(1): 73-75.